Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsFluphenazine decanoate (depot) and enanthate for schizophreniaRisperidone versus placebo for schizophreniaCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaNeurotransmitter transporters and their impact on the development of psychopharmacologyThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaGlutamate receptor ion channels: structure, regulation, and functionAdjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacyElucidating the role of neurotensin in the pathophysiology and management of major mental disorders.Glycine transport inhibitors for the treatment of schizophreniaMolecular targets for treating cognitive dysfunction in schizophrenia.Novel therapeutic drugs for neuropsychiatric disordersDifferential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.Novel diagnostic biomarkers for prostate cancer.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.The NMDA receptor as a target for cognitive enhancementGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonistFrom revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder.Newer molecules in the treatment of schizophrenia: A clinical updateIn vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.Disruption of hippocampal-prefrontal cortex activity by dopamine D2R-dependent LTD of NMDAR transmission.Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Pharmacogenomics: a path to predictive medicine for schizophrenia.NMDA neurotransmission as a critical mediator of borderline personality disorder.Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.On the hypes and falls in neuroprotection: targeting the NMDA receptor.Role of glutamate in schizophrenia: integrating excitatory avenues of research.Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor.Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?
P2860
Q22241447-589D512F-2C92-4EFD-87E1-B3C3605FBC19Q24188205-812B1616-F9F8-4C58-B6C8-39EC60AD0126Q24241041-1F120338-C41E-4260-A7DE-14C9D818BD82Q24646206-84ABB20C-61E7-48A1-8E3F-9690309FE18FQ24670273-06892B26-8E13-4878-B667-C055A6E0E31BQ28081110-5CCE00C8-5C5E-4AE5-96D5-1E410510287BQ28248687-3E5A80BD-C349-45A6-94A2-42C88398C500Q28263502-FDF658B2-9CFE-48FE-8782-7998032CB824Q28290774-9C58FCA9-07D1-4A64-834F-F9A1C912B98EQ28297813-6DF33A91-CE64-4750-B674-C306DBAA97AEQ30426586-64147579-103A-4967-863E-EF54C37D5507Q30477522-E78CE9C1-C06C-491F-AE19-D62D75195BF0Q30491310-EBC07335-7D80-4719-B127-F9E3881B8878Q34018299-0DCE89DA-6623-4CE7-AA6E-8545A991377DQ34230984-4E51D785-268E-4F3D-AD6D-5056727FFB7AQ34231678-9EE12CDE-0527-4538-A2C5-FF215A26F869Q34274859-2EFD1738-D74B-4307-92CA-6EF4569C2975Q34288139-DE6B8562-2D9F-4C02-B192-FD9B6F18270AQ34330678-69C5B9AF-9CDD-4687-A3C9-437450BAE363Q34377319-C402D49E-290E-4BC4-BA8E-5EAB0369D1E4Q34381226-FE78424E-25AE-4669-BCA9-615391DDC32FQ34610088-EED17F88-EC5B-41BA-8796-D24475FF4217Q34632695-1DEF7423-4EA3-4C61-B526-3300B4C98B9AQ34783324-7728A879-EE8B-48B6-874C-89BF76C9C443Q34843883-5F20DF8B-6B98-472A-9544-15AF44C5629FQ35051682-3019363D-5920-4DB9-9D2A-88301A146A6DQ36055697-7E6D1F1D-6409-4F06-9201-FFC461873C9AQ36247426-738E831C-A9AB-4F36-9978-2788417A7F01Q36252816-3DFB21C7-8259-4BFE-ADA3-F73C9D09D1ACQ36302850-F33807B1-8341-4FA7-AF80-26293D287513Q36310524-B5C38871-BB36-449A-A9E0-68A3F4CF9759Q36341739-ADFDBABE-4BB3-415B-AA48-D4EE47EAF8F0Q36758336-24512AB4-A7A0-42CE-886C-0E0EB001AB69Q36860053-82EB2516-2786-44A7-BC9F-A83624A24DCCQ36886717-DEE6B650-CF0D-430B-9EBB-39D2104A5F8BQ36930839-AD1237F7-8EDB-4DAB-8B62-F61480A941D1Q36958209-EB653B24-F8B8-4D5E-9149-33048C05FEA5Q37256709-1F71D16F-336D-47A2-951A-DD8B7EF6EE4CQ37327595-365E1AD5-EFAC-4970-9278-D1B295265B45Q37454485-379938E7-2A6C-44CF-BF84-18DFD37B92A1
P2860
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Glycine transporter I inhibito ...... the treatment of schizophrenia
@ast
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
Glycine transporter I inhibito ...... the treatment of schizophrenia
@nl
type
label
Glycine transporter I inhibito ...... the treatment of schizophrenia
@ast
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
Glycine transporter I inhibito ...... the treatment of schizophrenia
@nl
prefLabel
Glycine transporter I inhibito ...... the treatment of schizophrenia
@ast
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
Glycine transporter I inhibito ...... the treatment of schizophrenia
@nl
P2093
P1476
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
P2093
Guochuan Tsai
Hsien-Yuan Lane
Mian-Yoon Chong
Pinchen Yang
P356
10.1016/J.BIOPSYCH.2003.09.012
P407
P577
2004-03-01T00:00:00Z